ASSD (n = 64) | Control (n = 64) | P | |
---|---|---|---|
IMACS set scores | |||
MMT-8 (0–80) | 78 (71–80) | – | |
Patient’ VAS (0–10) | 4.0 (2.0–6.0) | – | |
Physician’ VAS (0–10) | 3.0 (0.0–5.0) | – | |
MYOACT (0–60) | 4.0 (0.5–2.5) | – | |
HAQ (0.00–3.00) | 0.67 (0.13–1.38) | – | |
CPK (U/L) | 208 (98–597) | 106 (78–161) | < 0.001 |
LDH (U/L) | 352 (243–590) | 346 (312–345) | 0.937 |
AST (U/L) | 24 (17–37) | 20 (16–23) | 0.009 |
ALT (U/L) | 24 (16–57) | 18 (13–25) | 0.030 |
Lung involvements | |||
Ground-glass | 46 (71.9) | – | |
Incipient pneumopathy | 40 (62.5) | – | |
Pulmonary fibrosis | 14 (21.9) | – | |
Pulmonary nodules | 11 (17.2) | – | |
FVC (% predict), n = 39 | 62.5 (48.0–73.5) | – | |
FEV1 (% predicted), n = 39 | 64 (49–77) | – | |
FEV1/FVC ratio, n = 39 | 0.90 (0.93–1.08) | – | |
DLCO2 (% predicted), n = 39 | 61.0 (37.8–73.0) | – | |
Treatment | |||
Prednisone | |||
Current use | 46 (71.9) | – | |
Dose (mg/day) | 10 (0–40) | – | |
Immunosuppressive drugs | 47 (73.4) | – | |
Azathioprine | 23 (35.9) | – | |
Mycophenolate mofetil | 11 (17.2) | – | |
Methotrexate | 14 (21.9) | – | |
Antimalarial | 4 (6.3) | – | |
Leflunomide | 2 (3.1) | – | |
Cyclosporine | 3 (4.7) | – | |
Cyclophosphamide | 1 (1.7) | – | |
Rituximab | 16 (25.0) | – | |
Cytokines | |||
YKL-40 (pg/mL) | 538.4 (363.4–853.1) | 270.0 (201.8–451.9) | < 0.001 |
IFNγ (pg/mL) | 0.02 (0.00–1.89) | 0.02 (0.00–0.17) | 0.876 |
TNFα (pg/mL) | 48.4 (31.0–66.3) | 39.6 (29.3–49.0) | 0.011 |